Mechanism of Action
IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. When administered intravenously, AGGRASTAT inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the PRISM-PLUS regimen of 0.4 mcg/kg/min over 30 minutes…
Clinical Trials (5)
Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function
Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention